Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990-2019).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 21 08 2023
accepted: 10 06 2024
medline: 15 6 2024
pubmed: 15 6 2024
entrez: 14 6 2024
Statut: epublish

Résumé

Kidney cancer, a type of urogenital cancer, imposes a high burden on patients. Despite this, no recent research has evaluated the burden of this type of cancer in the Middle East and North Africa (MENA) region. This study explored the burden of kidney cancer from 1990 to 2019 according to age, sex and socio-demographic index (SDI). The Global Burden of Disease (GBD) 2019 data was utilized to estimate the incidence, death, and disability-adjusted life-years (DALYs) caused by kidney cancer. These estimates were reported as counts and as age-standardised rates with 95% uncertainty intervals (UIs). The estimated age-standardised incidence, mortality, and DALY rates of kidney cancer in 2019 were 3.2 (2.8-3.6), 1.4 (1.2-1.6), and 37.2 (32.0-42.6) per 100,000, respectively. Over the period from 1990 to 2019, these rates have increased by 98.0%, 48.9%, and 37.7%, respectively. In 2019, the United Arab Emirates, Qatar, and Lebanon had the largest age-standardised incidence, mortality, and DALY rates. The smallest age-standardised incidence rates were seen in Yemen, Afghanistan, and the Syrian Arab Republic. Additionally, the smallest age-standardised mortality and DALY rates were observed in the Syrian Arab Republic, Yemen, and Morocco. The highest incidence rates were found among individuals aged 75-79 in both males and females. In 2019, the MENA/Global DALY ratio exceeded one for females aged 5-19 age and males aged 5-14, compared to 1990age groups in males. The burden of kidney cancer consistently rose with increasing SDI levels from 1990 to 2019. The increasing burden of kidney cancer highlights the urgent need for interventions aimed at improving early diagnosis and treatment in the region.

Identifiants

pubmed: 38877130
doi: 10.1038/s41598-024-64521-7
pii: 10.1038/s41598-024-64521-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13710

Subventions

Organisme : Shahid Beheshti University of Medical Sciences
ID : 43004455

Informations de copyright

© 2024. The Author(s).

Références

Collaboration GBoDC. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol. 8(3), 420–44 (2022).
doi: 10.1001/jamaoncol.2021.6987
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71(3), 209–49 (2021).
pubmed: 33538338
Scelo, G. & Larose, T. L. Epidemiology and risk factors for kidney cancer. J. Clin. Oncol. 36(36), 2018791905 (2018).
doi: 10.1200/JCO.2018.79.1905
Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. The Lancet 373(9669), 1119–1132 (2009).
doi: 10.1016/S0140-6736(09)60229-4
Lang, K., Danchenko, N., Gondek, K., Schwartz, B. & Thompson, D. The burden of illness associated with renal cell carcinoma in the United States. Urol. Oncol. 25(5), 368–375 (2007).
doi: 10.1016/j.urolonc.2007.02.014 pubmed: 17826652
Bai, X., Yi, M., Dong, B., Zheng, X. & Wu, K. The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Exp. Hematol. Oncol. 9(1), 1–15 (2020).
doi: 10.1186/s40164-020-00181-3
Zi, H. et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Milit. Med. Res. 8(1), 1–15 (2021).
Safiri, S. et al. The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990–2017. Sci. Rep. 10(1), 1–20 (2020).
doi: 10.1038/s41598-020-70840-2
Jani, C. et al. Trends of kidney cancer burden from 1990 to 2019 in European Union 15+ countries and World Health Organization regions. Sci. Rep. 12(1), 22368 (2022).
doi: 10.1038/s41598-022-25485-8 pubmed: 36572700 pmcid: 9792551
Vos, T. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet 396(10258), 1204–1222 (2020).
doi: 10.1016/S0140-6736(20)30925-9
Murray, C. J. L. et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet 396(10258), 1223–1249 (2020).
doi: 10.1016/S0140-6736(20)30752-2
Wang, H. et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet 396(10258), 1160–1203 (2020).
doi: 10.1016/S0140-6736(20)30977-6
Wang, Y. Smoothing Splines: Methods and applications (Chapman and Hall/CRC, 2019).
Wong, M. C. S. et al. Incidence and mortality of kidney cancer: Temporal patterns and global trends in 39 countries. Sci. Rep. 7(1), 15698 (2017).
doi: 10.1038/s41598-017-15922-4 pubmed: 29146923 pmcid: 5691143
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W. & Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat. Rev. 34(3), 193–205 (2008).
doi: 10.1016/j.ctrv.2007.12.001 pubmed: 18313224
McCredie, M. & Stewart, J. H. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 3(4), 323–31 (1992).
doi: 10.1007/BF00146885 pubmed: 1617119
Chow, W.-H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7(5), 245–257 (2010).
doi: 10.1038/nrurol.2010.46 pubmed: 20448658 pmcid: 3012455
Mills, K. T., Stefanescu, A. & He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 16(4), 223–237 (2020).
doi: 10.1038/s41581-019-0244-2 pubmed: 32024986 pmcid: 7998524
Mills, K. T. et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation 134(6), 441–450 (2016).
doi: 10.1161/CIRCULATIONAHA.115.018912 pubmed: 27502908 pmcid: 4979614
Nam, G. E. et al. Obesity, abdominal obesity and subsequent risk of kidney cancer: A cohort study of 2.33 million East Asians. Br. J. Cancer 121(3), 271–7 (2019).
doi: 10.1038/s41416-019-0500-z pubmed: 31231120 pmcid: 6738324
World Health Organization. Prevalence of Obesity Among Adults, Both Sex 2016. http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/obesity/atlas.html .
Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15(5), 288–298 (2019).
doi: 10.1038/s41574-019-0176-8 pubmed: 30814686
Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int. J. Cancer 114(1), 101–108 (2005).
doi: 10.1002/ijc.20618 pubmed: 15523697
Tsivian, M., Moreira, D. M., Caso, J. R., Mouraviev, V. & Polascik, T. J. Cigarette smoking is associated with advanced renal cell carcinoma. J. Clin. Oncol. 29(15), 2027–2031 (2011).
doi: 10.1200/JCO.2010.30.9484 pubmed: 21502558
Dai, X., Gakidou, E. & Lopez, A. D. Evolution of the global smoking epidemic over the past half century: Strengthening the evidence base for policy action. Tob. Control 31(2), 129–137 (2022).
doi: 10.1136/tobaccocontrol-2021-056535 pubmed: 35241576
Kabat, G., Silvera, S., Miller, A. & Rohan, T. A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. Br. J. Cancer 96(5), 845–849 (2007).
doi: 10.1038/sj.bjc.6603629 pubmed: 17311018 pmcid: 2360073
Lambe, M., Lindblad, P., Wuu, J., Remler, R. & Hsieh, C. Pregnancy and risk of renal cell cancer: A population-based study in Sweden. Br. J. Cancer 86(9), 1425–1429 (2002).
doi: 10.1038/sj.bjc.6600263 pubmed: 11986775 pmcid: 2375385
Manthey, J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: A modelling study. Lancet 393(10190), 2493–2502 (2019).
doi: 10.1016/S0140-6736(18)32744-2 pubmed: 31076174
Ziouziou, I., Shariat, S. F., Ajdi, F. & Khabbal, Y. Association of processed meats and alcohol consumption with renal cell carcinoma: A worldwide population-based study. Nutr. Cancer 73(11–12), 2665–2670 (2021).
doi: 10.1080/01635581.2020.1856388 pubmed: 33283531
Huang, J. et al. A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome. Eur. Urol. Focus 8(1), 200–9 (2022).
doi: 10.1016/j.euf.2020.12.020 pubmed: 33495133

Auteurs

Saeid Safiri (S)

Social Determinants of Health Research Center, Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. saeidsafiri@gmail.com.
Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. saeidsafiri@gmail.com.

Kamaleddin Hassanzadeh (K)

Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Amir Ghaffari Jolfayi (A)

Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyed Ehsan Mousavi (SE)

Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Kimia Motlagh Asghari (K)

Social Determinants of Health Research Center, Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Seyed Aria Nejadghaderi (SA)

HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Nima Naghdi-Sedeh (N)

Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Maryam Noori (M)

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Mark J M Sullman (MJM)

Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.
Department of Social Sciences, University of Nicosia, Nicosia, Cyprus.

Gary S Collins (GS)

Centre for Statistics in Medicine, NDORMS, Botnar Research Centre, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Ali-Asghar Kolahi (AA)

Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a.kolahi@sbmu.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH